Endolymphatic radiotherapy in malignant lymphomas: its potential "prophylactic" value in cases with negative lymphograms.
From 1961 to 1969 426 patients (208 with Hodgkin's disease and 218 with non-Hodgkin's lymphoma) underwent endolympatic radiotherapy with Lipiodol 131I at the National Cancer Institute of Milano. For this study, only those patients with stage I, II, or III disease (with or without systemic symptoms), who were not previously treated, and who had a complete follow-up were reviewed. It appears that while in the cases where there is lymphographic evidence of involved lymph nodes, endolymphatic radiotherapy is not of value, in the cases with apparently negative lymphography, endolymphatic radiotherapy can reduce the incidence of relapse in the inguino-retroperitoneal nodes to a statistically significant degree.
D000005:Abdomen; D000328:Adult; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007459:Iodized Oil / Q000627:therapeutic use; D008198:Lymph Nodes / Q000528:radiation effects*; D008207:Lymphatic Metastasis; D008223:Lymphoma / Q000532:radiotherapy*; D008297:Male; D010388:Pelvis; D012187:Retroperitoneal Space
D007457:Iodine Radioisotopes; D007459:Iodized Oil